Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review

Abstract: Behavioral and psychological symptoms represent common complications in patients with different types of dementia. Predominantly, they comprise psychosis, agitation and mood disorders, disinhibited behavior, impairment of the sleep and wakefulness rhythm, wandering, perseveration, pathological collecting, or shouting. Their appearance is related to more rapid progression of the disease, earlier institutionalization, use of physical restraints, and higher risk of mortality. Consequently, appearance of behavioral and psychological symptoms of dementia leads to higher costs of care provided and greater distress for caregivers. Clinical guidelines recommend nonpharmacological approaches as the first choice in the treatment of behavioral and psychological symptoms. Pharmacological therapy should be initiated only if the symptoms were not the result of somatic causes, did not respond to nonpharmacological interventions, or were not caused by the prior medication. Acetylcholinesterase inhibitors, memantine, antipsychotic drugs, antidepressants, mood stabilizers, and benzodiazepines are used. This review summarizes the current findings about the efficacy and safety of the treatment of the neuropsychiatric symptoms in dementias with psychopharmaceuticals. Recommendations for treatment with antipsychotics for this indication are described in detail as this drug group is prescribed most often and, at the same time, is related to the highest risk of adverse effects and increased mortality.

Keywords: dementia, behavioral and psychological symptoms, treatment, psychopharmaceuticals, adverse effects

Introduction

Behavioral and psychological symptoms of dementia (BPSD) represent common complications in patients with different types of dementia. Predominantly, they comprise psychosis, agitation and mood disorders, disinhibited behavior, impairment of the sleep and wakefulness rhythm, wandering, perseveration, pathological collecting, or shouting. Usually, neuropsychiatric symptoms are not isolated. They tend to appear in certain clusters. These clusters could be classified according to the most prevalent symptoms as predominantly affective, psychotic, hyperactive, or apathic. The occurrence of BPSD has been documented in most types of dementias – Alzheimer’s disease (AD), vascular dementia (VaD), dementia in Parkinson’s disease, frontotemporal dementia (FTD), and in mild cognitive impairment.

To assess the presence and severity of the symptoms, it is recommended to use assessment scales like Neuropsychiatric Inventory (NPI) or Behavioral Pathology in Alzheimer’s Disease Rating Scale.

Most patients with dementia develop at least one of the BPSD in the course of their disease. Their appearance causes increased distress for the patient and those
around – mostly the caregivers. Presence of BPSD is related to more rapid progression of the disease (especially in depressive and psychotic symptoms), earlier institutionalization, use of physical restraints, and higher risk of mortality. As a result, the costs of care provided increase.

It is difficult to choose safe and effective pharmacological treatment because of the paucity of data from randomized controlled trials (RCTs). Most often, antipsychotic drugs are prescribed, although there is no solid evidence of their efficacy in individual neuropsychiatric symptoms. Concurrently, the administration of antipsychotic drugs entails the risk of occurrence of adverse effects. A study by van der Spek et al showed alarming results. Based on an index comprising indication, dosage, drug interactions, duplicate administration, and duration of treatment, the authors determined that the BPSD were correctly treated with psychopharmaceuticals in accordance with all criteria in only 10% of patients.

This review summarizes the current findings on efficacy and safety of the treatment of the neuropsychiatric symptoms in dementias with psychopharmaceuticals. Recommendations about treatment with antipsychotics in this indication are described in detail as this drug group is prescribed most often and, at the same time, is related to the highest risk.

Approach to the treatment of BPSD

The causes for the development of the BPSD are usually multifactorial. Causal and contributing factors could be classified as biological, psychological, social, and environmental. Individual factors differ in their degree of modifiability. Before the initiation of any treatment for BPSD, it is necessary to examine the patient carefully and remove any possible precipitating factors. Infections (including dental infections), pain, and dehydration are the most common triggers of neuropsychiatric symptoms. BPSD could also be induced by visual or hearing deficit. It is necessary to reduce common and unreasonable polypharmacy. Administration of drugs with anticholinergic effects (eg, urological drugs) and benzodiazepines is not appropriate. Digitalis and diuretics are also risky regarding the occurrence of the BPSD.

Clinical guidelines recommend nonpharmacological approaches as the first choice in the treatment of BPSD. Most evidence favors behavioral therapy, interventions focused on caregivers, communication skills training of the staff nursing the patients with dementia, and music therapy with a transient effect on agitation and anxiety. Other approaches include aromatherapy (lavender and lemon balm in particular), massages, and bright light therapy, all of which can contribute to alleviation of BPSD.

Pharmacological therapy should be initiated only if the symptoms did not have somatic causes or did not respond to nonpharmacological interventions or were not caused by prior medication. Indicated and well-performed pharmacotherapy could prevent hazardous physical restraint of elderly patients. According to Kuronen et al, more than half of hospitalized patients with dementia had been physically restrained within the previous 24 hours. Psychotic symptoms and the use of benzodiazepines constituted the risk factors. Conversely, patients using antipsychotics and antidepressants were physically restrained less often. Acetylcholinesterase inhibitors (AChEI), memantine, antipsychotic drugs, antidepressants, mood stabilizers, and benzodiazepines comprise the medication for the treatment of BPSD.

Antidepressants

Depression and anxiety are among the most common behavioral disorders in dementia. Antidepressants can influence cognition by direct action on specific neurotransmitters or secondarily, by improving the depressive symptoms. Administration of the antidepressant can improve not only the cognition and affective symptoms, but partially, also agitation and aggression. Given the profile of adverse effects, tricyclic antidepressants are totally inappropriate for the elderly population. Selective serotonin reuptake inhibitors (SSRIs), particularly sertraline, citalopram, and escitalopram, have mild efficacy and good tolerance. Analyses of the effect of the antidepressants on neuropsychiatric symptoms other than depression in patients with dementia were published. Two placebo-controlled studies showed that the treatment with sertraline and citalopram was related to significant reduction in agitation. A recent study showed the efficacy of an average dose of citalopram on moderate agitation in patients with a mild degree of cognitive impairment. Conversely, patients with severe agitation and a severe cognitive deficit were more likely to experience adverse effects. Citalopram also partially alleviated delusions, anxiety, irritability, and emotional lability. However, it worsened cognitive functions and caused slight prolongation of the QTc interval on ECG. In the study by Viscogliosi et al, citalopram was as efficient in treatment of agitation as olanzapine and quetiapine, and it was tolerated better. This study did not record any effect of citalopram on the QTc interval or cognitive functions. Generally, administration of citalopram and escitalopram in higher doses is not recommended in elderly patients with dementia given the risk of prolonging the QTc interval. Furthermore, during treatment with SSRI, it is necessary to monitor the risk of development of hyponatremia, nausea,
vomiting, diarrhea, tremor, gastrointestinal bleeding, and sleep deterioration. There is less evidence for efficacy and tolerance of trazodone in the treatment of BPSD. More data are available for VaD and FTD. Only a small open study showed the positive effect of mirtazapine.

**Anticonvulsants and mood stabilizers**
From controlled trials studying mood anticonvulsants/mood stabilizers, there are data concerning carbamazepine and valproate only. Carbamazepine was effective in the treatment of noncognitive symptoms of dementia, especially agitation, aggression, and hostility. Its administration carries several adverse effects including hematotoxicity. It is also a strong inducer of cytochrome oxidase system P450. In the treatment of BPSD, valproate did not differ from the placebo, and its administration was burdened by frequent adverse effects. Moreover, it can adversely affect cognitive functions. The Cochrane Database System Review showed that low doses of valproate were ineffective, while the higher doses led to frequent adverse effects like sedation (odds ratio [OR]=2.64), gastrointestinal problems (OR=4.12), urinary tract infections (OR=3.02), and falls (OR=2.08). Currently, there is only limited clinical experience and evidence for the use of lamotrigine and gabapentin. Based on the available data, anticonvulsants cannot be recommended for common use for this indication despite the possible benefits in some patients.

**Acetylcholinesterase inhibitors and memantine**
AChEI and memantine have only a mild effect on BPSD. According to a meta-analysis, the effect of AChEI on BPSD is statistically significant; however, the clinical outcome remains unclear. The effect could be visible after several weeks of administration. Mostly, they tend to influence symptoms of depression, anxiety, and tension. Memantine is more effective on agitation, delusions, hallucinations, and aggression. The influence of AChEI and memantine on different symptoms provides a good theoretical premise for their use in some combination. This was determined by a recent meta-analysis, which showed a significantly higher effect of memantine in combination with donepezil in the treatment of BPSD than the administration of donepezil in monotherapy. Administration of AChEI could be connected with diarrhea, nausea, vomiting, as well as bradycardia and syncope. Caution should be taken especially in patients with arrhythmias or patients using bradycardia-inducing medication. Data supporting the efficacy of gingko biloba extract EGb 761 on BPSD (except psychosis) and the reduction of the distress on the caregivers are available.

**Benzodiazepines**
Benzodiazepines are prescribed for up to 15%–30% of patients with dementia living in medical centers and homes for the elderly. According to a Finnish cohort study, patients with Alzheimer’s dementia have 4.5 times higher risk of being prescribed benzodiazepines in comparison with their peers without dementia. Administration of these drugs is associated with deterioration of cognitive functions, sedation, paradoxical disinhibition, risk of falls, and fracture of the femoral neck. It is recommended not to administer benzodiazepines to the patients with dementia. For necessary cases, drugs with a shorter duration of action (midazolam, cinoxazepam, and oxazepam) could be used singularly, but they should not be administered under hypnotic indication. “Z-hypnotics” (zopiclone, zolpidem, and zaleplon) can have similar adverse effects among elderly patients as benzodiazepines. In patients with dementia, we use them only for a limited time in low doses to treat insomnia.

**Antipsychotics**
Antipsychotics are prescribed for up to 60% of patients with dementia treated in medical centers or homes for the elderly. Prescriptions of antipsychotics slightly decreased following warnings from the Food and Drug Administration (FDA) in 2005 (significantly increased risk of mortality for second-generation antipsychotics [A2G] in comparison with the placebo) and 2008 (warning extended to first-generation antipsychotics [A1G]). Currently, A2G are prescribed more often than the A1G. Common use of A2G is controversial for the following three reasons: in studies performed, the effect size (ES) was low, tolerance was rather poor, and there was a probable connection to increased mortality.

**Efficacy of antipsychotics**
From the A1G group, the most available data concern haloperidol, which was effective in suppressing aggression (in dose of 1.2–3.5 mg/day; ES 0.31; 95% CI 0.49 to –0.13). On the other hand, it had only a minor effect on agitation and psychotic symptoms. Thus, it is not certain if the benefits outweighed the adverse effects of this drug.

The efficacy of A2G in the treatment of BPSD was observed by more than 20 randomized controlled studies. Given the lower occurrence of extrapyramidal symptoms (EPS), A2G are tolerated better and their efficacy is comparable with A1G. In a study, risperidone was more effective
than haloperidol. Data are available to support the efficacy of olanzapine, risperidone, quetiapine, aripiprazole, and amisulpride to a certain degree. Recent findings favor risperidone and olanzapine as a drug of choice for the management of psychosis and aggression in patients with dementia.1

Extensive study evaluated off-label use of A2G in patients with BPSD in 14 placebo-controlled trials. Certain symptoms were followed, for example, psychosis, aggression, and mood changes. Overall, ES was poor, but statistically significant (0.12–0.20) in aripiprazole, olanzapine, and risperidone. Quetiapine proved to be ineffective.40 When comparing the antipsychotic effect, only risperidone performed better than the placebo. Similarly, an extensive blinded, 36-week-long, multicenter CATIE-AD study, which compared the effects of olanzapine, risperidone, and quetiapine in 421 patients with Alzheimer’s dementia, showed the higher efficacy of risperidone and olanzapine on BPSD in comparison with the placebo. This did not apply to quetiapine.41 Concurrently, it shows that the relatively poor efficacy of antipsychotics is accompanied by noticeable adverse effects.

A meta-analysis of 23 RCTs showed the efficacy of A2G in the treatment of BPSD in comparison with the placebo.42 Aripiprazole and risperidone performed better than the placebo in reducing the psychiatric symptoms. With regard to the effect on cognitive functions, aripiprazole, risperidone, olanzapine, and quetiapine were effective.

The results of placebo-controlled studies may underestimate the real efficacy of antipsychotics on BPSD because of the implemented methodology and selection of enrolled patients. Unpublished data from studies concerning clozapine, paliperidone, asenapine, and ziprasidone are available. In the treatment of BPSD, these antipsychotics are rarely used or not at all.9 Also, the benefits of administration of antipsychotics to treat BPSD longer than 12 weeks remain unclear although 60% of patients with dementia are administered this type of medication for longer than 6 months.43 Important findings were brought by a post-hoc analysis of the CATIE-AD trial. It determined that insufficient improvement after 2 weeks of the treatment with antipsychotic medication is a significant predictive factor of nonresponsiveness after 8 subsequent weeks. Therefore, it would be beneficial to change the treatment.44

Administration of D2/D3 receptor blocker amisulpride to treat psychosis in patients with dementia using a low-dose therapeutic window of 50 mg/day has only had a theoretical foundation based on imaging studies.45

Adverse effects of antipsychotics
The use of A1G in patients with dementia is restricted by the occurrence of EPS – Parkinsonism, dystonia, and tardive dyskinesia. Prolongation of the QTc interval on ECG and arrhythmias is also more common. During A2G administration, motor adverse effects are less expressed; however, thromboembolic episodes, aspiration pneumonia, metabolic symptoms, falls, and deterioration of cognitive performance are more common. Both groups of antipsychotics carry a higher risk of stroke.46,47

According to the CATIE-AD study, the adverse effects of olanzapine, risperidone, and quetiapine outweighed their benefits. Parkinsonism occurred more often during treatment with olanzapine and risperidone (12%) than with quetiapine (2%) or placebo (1%). During treatment with olanzapine and risperidone, states of confusion were registered more often (in 18% and 11% of patients, respectively). The occurrence of sedation (15%–24%) and weight gain did not differ among the compared antipsychotics. The incidence of falls, fractures, and other injuries was frequent during the treatment with antipsychotics (7%–17%); however, it was comparable with the placebo (15%). From among the severe adverse effects, stroke and transitory ischemic attack were rarely described during the treatment with both antipsychotics (1%–2%) and placebo (1%).41 A review of 18 placebo-controlled studies concerning the use of A2G in patients with dementia brought similar outcomes.48 The EPS occurred more often in risperidone and olanzapine. Conversely, in aripiprazole and quetiapine, they were comparable with the placebo. The weight gain was most often caused by olanzapine and risperidone. The excessive sedation was described in all studied antipsychotics. Given its minor potential to induce EPS, quetiapine is appropriate for the treatment of psychotic symptoms in Parkinson’s disease or, as the case may be, Lewy body dementia.

The negative effect of the antipsychotic medication on cognitive functions has been discussed. The meta-analysis did not prove this effect of antipsychotics.49 Conversely, the severity of dementia and the duration of treatment worsened cognitive deterioration. Given the limited data, authors recommend interpreting these conclusions with caution. Nevertheless, they assume that falls and cerebrovascular accidents (CVAs) represent a higher risk of antipsychotic medication than its effect on cognitive functions.50

Mortality during treatment with antipsychotics
In 2005, the US FDA issued a warning concerning increased mortality of the patients with dementia and BPSD treated with A2G. An identical warning from the European Medicines Agency (EMA) followed. The information was included in the summary of product characteristics (SPC) of antipsychotics. The warning was based on the results
from published and unpublished data and, particularly, on the conclusion of a meta-analysis of 17 randomized controlled studies. It determined that there was approximately twice the risk of mortality during therapy with olanzapine, risperidone, quetiapine, and aripiprazole in comparison with the placebo.

Another meta-analysis brought similar outcomes. Observational studies brought data from larger groups of patients during the long-term administration of antipsychotics. A study concluded by Wang et al\(^5\) found the mortality risk increased by 30% during treatment with A1G in comparison with A2G. Another study showed similar results (risk increase by 26% in A1G versus A2G).\(^5\) On the contrary, another 1-year-long cohort study showed that the mortality risk was lower by 17% during treatment with A2G in comparison with A1G administration.\(^5\) None of these studies evaluated mortality for individual antipsychotics. In 2008, the warning was also extended to A1G.\(^\)\(^4\)

The risk of mortality grows with an increasing dose of the antipsychotic medication, and it is at its highest level shortly after initiation of the therapy.\(^9,50,51\) Some newer studies focused on the risks of individual antipsychotics. A retrospective 6-month-long study showed the highest relative risk (RR) of mortality during administration of haloperidol (RR=1.54). Risperidone (RR=1) and olanzapine (RR=0.99) had comparable risks. The treatment with quetiapine was related to the lowest risk of mortality (RR=0.73). Haloperidol carried the highest risk within the first 30 days of administration, and afterward, risk sharply declined. For other medications, the risk was most significant within the initial 120 days of administration and slowly decreased during the following 60 days. The relative safety of quetiapine was balanced by low efficacy on aggression, agitation, and psychosis.\(^8\) An observational study\(^55\) showed the highest mortality risk during treatment with higher doses of haloperidol and the lowest risk during administration of low doses of quetiapine. The survival of patients with dementia treated with antipsychotics compared with the placebo patients decreased significantly in association with the duration of treatment in the 36-month placebo-controlled DART-AD study (Dementia Antipsychotic Withdrawal Trial). Seventy percent of patients on antipsychotics survived 12 months in comparison with 76% of patients in the placebo group. However, only 30% of patients on antipsychotics survived 36 months in comparison with 59% of patients in the placebo group.\(^56\)

However, the study results may be distorted. Most studies are performed in a vulnerable group of seniors living in homes for the elderly, or in similar facilities. These individuals are primarily more ill and are at greater risk than their peers living at home. In mortality studies, patients without antipsychotic medication are enrolled as a control group for the users of antipsychotics. There could be a great difference between these groups in severity of dementia and occurrence of somatic risks, which is reflected in the observed mortality.\(^9\)

The most common causes of death during the treatment of BPSD with antipsychotic drugs are cardiovascular, cerebrovascular, respiratory, and infectious (pneumonia) diseases.

In controlled studies, risk of CVA in patients with dementia using antipsychotics was 1.3–2 times higher in comparison with controls.\(^57\) Antipsychotics can contribute to the development of CVA through orthostatic hypotension, hyperprolactinemia causing endothelial dysfunction or thrombogenic effect. After an episode of hypotension, catecholamines are released and cause vasoconstriction. Antipsychotic-induced sedation may lead to venous stasis and dehydration related to vasoconstriction. The risk of CVA is comparable in A1G and A2G and peaks within the initial weeks of antipsychotics administration. Diabetes mellitus, hypertension, atrial fibrillation, VaD, and occurrence of stroke in the medical history represent preexisting risk factors for developing CVA.\(^9\) A recent meta-analysis of observational studies showed increased risk (OR 1.49; 95% CI 1.24–1.77) in A1G. However, there is only a slightly increased risk during the administration of A2G (OR 1.31; 95% CI 0.74–2.30). Administration of any specific antipsychotic drug entailed low risk (OR 1.17; 95% CI 1.08–1.26) of CVA.\(^58\)

The treatment with both first and second generation of antipsychotics is related to increased risk of developing pneumonia.\(^9\) Possible causes comprise aspirations because of EPS, dysphagia, sedation, or dry mouth influenced by the effects of antipsychotics on dopamine, cholinergic, and histamine H1 receptors.\(^9\)

Elderly patients with dementia should be monitored due to cardiovascular adverse effects. Prolonging the QTc interval on ECG may result in Torsade des points or other potentially fatal ventricular arrhythmia. Among the available antipsychotics, sertrindole, haloperidol, quetiapine, and ziprasidone prolong the QTc interval.\(^40\) It is necessary to be aware of this complication when treating patients with cardiac diseases and using other drugs that prolong the QTc interval. Given the risk of orthostatic hypotension, olanzapine should not be administered to elderly patients who previously underwent syncope.\(^61\)

The treatment with antipsychotics is related to the high risk of venous thromboembolism (VTE).\(^62\) This information is listed in the SPC. An extensive study of cases and
controls (n=72,591) in patients with dementia determined the increased risk of VTE (OR 1.23 [1.01–1.60]) during the administration of antipsychotics in comparison with not using the medication.\[61\] There was no difference between the treatment with A1G and A2G. The relation of VTE to individual medical products has not been studied in patients with dementia.

Comparatively speaking, little data are available on the incidence of metabolic symptoms in patients with BPSD treated with antipsychotics. The CATIE-AD study described weight gain during the use of olanzapine and quetiapine.\[64\] Rondanelli et al\[65\] did not observe any weight gain, appearance of type 2 diabetes mellitus, or abnormalities of lipid metabolism during treatment with low doses of A2G in patients with dementia. According to current findings, it is not clear to what extent potential metabolic symptoms of antipsychotics administered to patients with dementia can contribute to their increased mortality.

Some data give evidence about the possible contribution of EPS, falls, and deterioration of cognitive functions during administration of antipsychotics in increased mortality of patients with dementia.\[46\]

**Recommendations for the treatment of BPSD with antipsychotics**

First, we should search for treatable causes and triggers of neuropsychiatric symptoms like infection, constipation, pain, or polypharmacy. Antipsychotics can be used only if nonpharmacological approaches failed, the patient endangers himself or his surroundings, or the symptoms cause distress to the patient or the caregiver. Before the use of antipsychotics, we should consider whether we could use less effective but safer pharmacological approaches (AChEI or antidepressants). Before the initiation of the treatment with antipsychotics, we should assess the individual risks (particularly the cardiovascular risks) and modify the choice of the medication accordingly. The administration of antipsychotics should always be initiated at a low dose to be titrated up to the minimum effective dose. We should continuously monitor the adverse effects and choose the lowest effective doses possible. The recommended range of doses of antipsychotics is listed in Table 1. The treatment with antipsychotics should be time limited. Initially, it is appropriate to reassess the patient’s status at least monthly (or more often, if there was high risk of adverse effects). Later, it should be assessed every 3 months. We should regularly monitor the physical parameters, laboratory variables, and ECG. The initial recommended interval is every 3 months, later every 6 months. If the condition of the patient did not improve after 2–4 weeks, an increase in the dose or change of the antipsychotic medication would be appropriate. However, first, we should always carefully evaluate the benefits and risks of such an intervention. Conversely, if the condition of the patient improved with the antipsychotic treatment, an attempt to withdraw the antipsychotics should follow within 6–12 weeks.\[1,6,46\] The long-term administration of antipsychotics is recommended only in patients with extremely severe initial manifestations of BPSD. In practice, it is not easy to estimate the corresponding duration of the treatment with antipsychotics in patients with dementia. We do not have sufficient data to clearly set the conditions of termination of the treatment. The analysis by the Cochrane Database System Review involved nine randomized studies.\[66\] For most patients, discontinuation of the antipsychotic treatment would make no difference. However, two studies showed that the discontinuation of the antipsychotic medication could lead to a relapse, even though it had a positive short-term effect on agitation and psychosis. Two other studies confirmed the risk of this approach in patients with a high degree of initial symptoms (NPI≥14 points). Occurrence of auditory hallucinations is particularly hazardous. Their presence was related to the significant risk of relapse following the discontinuation of risperidone after 4 weeks of treatment in comparison with the group of patients who continued the antipsychotic medication.\[67\] The American Psychiatric Association has recently published guidelines for the use of antipsychotics to treat BPSD.\[11\] Recommendations are summarized in Table 2.

**Potential drug interactions during the treatment of BPSD**

Elderly patients are at risk of the adverse effects of the medication because of concurrent diseases, polypharmacy, physiological changes in pharmacokinetics and pharmacodynamics of several drugs, and sometimes, because of noncompliance caused by a cognitive deficit or depression. During the BPSD treatment, interactions between administered antipsychotics and long-term prescribed cognition enhancers may occur.

### Table 1  Recommended daily doses of antipsychotics to treat BPSD and the available drug forms

<table>
<thead>
<tr>
<th>Antipsychotic</th>
<th>Daily dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risperidone (tbl., sol.)</td>
<td>0.25–1 mg</td>
</tr>
<tr>
<td>Olanzapine (tbl., inj.)</td>
<td>2.5–7.5 mg</td>
</tr>
<tr>
<td>Quetiapine (tbl.)</td>
<td>12.5–150 mg</td>
</tr>
<tr>
<td>Aripiprazole (tbl., inj.)</td>
<td>5–10 mg</td>
</tr>
<tr>
<td>Haloperidol (tbl., gtt, inj.)</td>
<td>0.5–5 mg</td>
</tr>
</tbody>
</table>

**Abbreviation:** BPSD, behavioral and psychological symptoms of dementia.
AChEI have relatively few pharmacokinetic interactions. Metabolism of donepezil and galantamine could be influenced by substrates, inductors, or inhibitors of cytochrome oxidase system CYP2D6 and CYP3A4. Given the metabolism by two isoenzymes, the competitive inhibition by others of their substrates does not have to be clinically relevant (e.g., during concurrent administration of donepezil and sertraline). Paroxetine, a strong CYP2D6 inhibitor, can increase the levels of galantamine by 30%–40%.68 Interactions tend to get worse during hepatic and renal impairment. Rivastigmine and memantine have extrahepatic metabolism (Table 3).

The concurrent administration of AChEI with anticholinergic-acting medication is among the clinically significant pharmacodynamic interactions. This involves several antipsychotic and antidepressant medications for the treatment of BPSD. Antihistamines and some bronchodilators also have anticholinergic effects. These drugs deteriorate cognition and have an antagonistic effect on AChEI. Still, one-third of patients treated with AChEI are concurrently prescribed the anticholinergic-acting medication.69 AChEI modify cardiac and cerebral functions by stimulating the parasympathetic system. Inhibition of cholinesterase reduces acetylcholine degradation and contributes to slowing the heart rate. AChEI also increase blood pressure through central M1 and M2 cholinergic receptors. Hence, the interaction with antipsychotics or antidepressants that slow the heart rate and prolong the QTc interval on ECG leads to bradycardia and can increase the risk of syncope and mortality. Metabolism and conceivable interaction of cognitive enhancers are summarized in Table 3.

**Conclusion**

The behavioral and psychological symptoms represent a common complication in patients with dementia. Predominantly, they comprise psychosis, agitation and mood disorders, disinhibited behavior, impairment of the sleep and wakefulness rhythm, wandering, perseveration, pathological collecting, shouting, etc. Their occurrence is related to more rapid progression of the disease, earlier institutionalization, use of physical constraints, and higher risk of mortality. It leads to higher costs of care provided and greater distress for caregivers. The authors of this study believe that non-pharmacological approaches should be the first choice in the treatment of behavioral and psychological symptoms.

### Table 2 Recommendations on the use of antipsychotics to treat BPSD

<table>
<thead>
<tr>
<th>Steps</th>
<th>Recommended procedures</th>
</tr>
</thead>
</table>
| Assessment of BPSD                         | 1. Patients with dementia should be assessed for the type, frequency, severity, clinical pattern, and timing of the symptoms (1C)  
2. Assess for pain and other potentially modifiable factors and for subtypes of dementia that may influence the choice of treatment (1C)  
3. Use quantitative measures to assess agitation and psychosis, if present (1C)                                                                                           |
| Development of comprehensive treatment plan| 4. Individualized treatment plan includes appropriate nonpharmacological and pharmacological interventions (1C)                                                                                                       |
| Assessment of benefits and risks of antipsychotic treatment for the patient | 5. Antipsychotic medication should be used for treatment of agitation or psychosis only when symptoms are severe or dangerous and/or cause significant distress to the patient (1B)  
6. Review response to nonpharmacological interventions prior to use of an antipsychotic medication (1C)  
7. If feasible, discuss risk/benefit with the patient and obtain his/her or the caregiver’s consent (1C)                                                                 |
| AP treatment – dosage, duration, and monitoring | 8. Initiate at a low dose to be titrated up to the minimum effective dose as tolerated (1B)  
9. If significant adverse effects occur, review the patient’s status and taper or discontinue the antipsychotic medication (1C)  
10. If no significant response occurs after 4 weeks of an adequate dose, taper and withdraw the medication (1B)  
11. If positive response occurs, consider and discuss tapering the dose with the patient/surrogate regarding experience with tapering attempts (1C)  
12. If adequate response occurs, the dose of antipsychotic medication could be tapered or withdrawn, unless the patient experienced recurrence of symptoms with prior attempts at tapering (1C) |
| Use of specific antipsychotic medication, depending on clinical context | 13. If the dose of antipsychotic medication is being tapered, assess the symptoms at least monthly for a minimum of 4 months after discontinuation to identify recurrence of symptoms (1C)  
14. In the absence of delirium, haloperidol should not be used as a first-line agent (1B)  
15. Long-acting injectable antipsychotics should not be used, unless it is indicated for co-occurring psychotic disorder (1B)                                                                 |

**Notes:** Recommendations in brackets: 1 = recommended – benefits of the intervention outweigh its harms, 2 = uncertain benefit/potential harm ratio. Strength of evidence: A = high, B = moderate, C = low.67

**Abbreviation:** BPSD, behavioral and psychological symptoms of dementia.
The pharmacological therapy should be initiated only if the symptoms were not caused by somatic causes, did not respond to nonpharmacological interventions, or were not caused by prior medication. AChEI, memantine, antipsychotics, antidepressants, mood stabilizers, and benzodiazepines are used. In practice, antipsychotics are prescribed most often, although we do not possess solid evidence about their efficacy on individual neuropsychiatric symptoms, and concurrently, their administration is related to high risk of occurrence of adverse effects and increased mortality. Therefore, antipsychotics should be used only when safer interventions fail or when the patient endangers him/herself or his/her surroundings with his/her symptoms or when the symptoms cause excessive distress to the patient or the caregivers. Prior to initiation of the antipsychotic medication, somatic examination including ECG should be performed, individual risk should be assessed, and the choice of specific medication should be assessed differentially. Generally, compared with the common population, lower doses should be used and titrated gradually. During the treatment, physical parameters and occurrence of adverse effects should be monitored regularly. The withdrawal of antipsychotic medication should be attempted in time in patients with lower initial intensity of symptoms. When choosing the medication, pharmacokinetic and pharmacodynamic interaction with AChEI and memantine used by majority of patients with dementia should be considered.

### Acknowledgments

This paper was supported by the research project PROGRES Q40 run at the Medical Faculty of Charles University and by MH CZ – DRO (UHHK 00179906) and by the project Excellence 2018, run at the Faculty of Informatics and Management of the University of Hradec Kralove, Czech Republic.

### Author contributions

All authors contributed equally toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

### Disclosure

The authors report no conflicts of interest in this work.
References


